Target intelligence / Profile preview

Rho family GTPase 1 (RND1)

Target
RND1
Molecular classification
Enzyme (Small GTPase), Signaling protein, Rho family GTPase
01

Overview

Rho family GTPase 1 (RND1) is a small (~21 kDa) signaling GTPase protein, encoded by the RND1 gene and belonging to the Rho family subgroup known as Rnd[1][3]. Unlike most GTPases, RND1 lacks intrinsic GTPase activity, constitutively binds GTP, and does not cycle between active/inactive forms in the standard manner[3][4]. RND1 is chiefly involved in regulating actin cytoskeleton organization and cell structure in response to extracellular signals[1][3][4]. In neurons, it participates in extending neurites and affects microtubule dynamics[2][3]. The protein interacts with several signaling effectors, including stathmin2 (neuronal growth), GRB7, PLXNB1, PDE6D, ARHGAP5, and UBXD5[1]. Disruption of its function or aberrant signaling via RND1 and related Rho GTPases has been implicated in cancer progression and developmental disorders[2][3]. The lack of intrinsic GTPase activity distinguishes RND1 from many classical Rho proteins[4].

Other names
RND1Rho-related GTP-binding protein Rho6RHO6ARHSRHOSRho family GTPase 1ras homolog gene family member SRho6
02

Mechanism of action

For theoretical drugs or tool compounds: Inhibition or modulation of GTPase activity; Disruption or enhancement of actin cytoskeleton organization; Affecting downstream effectors (e.g., stathmin2, microtubule-regulating proteins).

03

Biological functions

Regulation of actin cytoskeleton organizationSignal transductionNeurite extension and microtubule depolymerization (neuronal growth)Cell migration and polarityMorphogenesis, cell movement, division, gene expression, cytoskeleton reorganization (roles described for RHO family)
04

Disease associations

Cancer (altered RHO GTPase signaling seen in human malignancies)Neurological development (neurite extension/disruption)Cepacia syndromeOther roles possible in cell migration abnormalities, development
05

Safety considerations

Cell toxicity due to disruption of essential cytoskeletal functions.Difficulty achieving specificity due to the highly conserved nature of family members and overlap in downstream pathways.Unknown off-target effects if used in clinical settings.
06

Interacting drugs

No clinically approved drugs directly targeting RND1 are reported in the retrieved sources. Molecules targeting Rho family GTPases generally include tool compounds in research, but no direct therapeutic agents for RND1 are listed
07

Biomarkers

None are established or reported for patient selection or efficacy according to provided sources

Beyond the preview

Go deeper on Rho family GTPase 1 (RND1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rho family GTPase 1 (RND1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call